{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:03:03Z","timestamp":1776276183444,"version":"3.50.1"},"reference-count":115,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antioxidants"],"abstract":"<jats:p>In this article we have reviewed the potential role of coenzyme Q10 (CoQ10) in the pathogenesis and treatment of a number of less common age-related disorders, for many of which effective therapies are not currently available. For most of these disorders, mitochondrial dysfunction, oxidative stress and inflammation have been implicated in the disease process, providing a rationale for the potential therapeutic use of CoQ10, because of its key roles in mitochondrial function, as an antioxidant, and as an anti-inflammatory agent. Disorders reviewed in the article include multi system atrophy, progressive supranuclear palsy, sporadic adult onset ataxia, and pulmonary fibrosis, together with late onset versions of Huntington\u2019s disease, Alexander disease, lupus, anti-phospholipid syndrome, lysosomal storage disorders, fibromyalgia, Machado-Joseph disease, acyl-CoA dehydrogenase deficiency, and Leber\u2019s optic neuropathy.<\/jats:p>","DOI":"10.3390\/antiox11112293","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T03:09:30Z","timestamp":1669000170000},"page":"2293","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Coenzyme Q10: Role in Less Common Age-Related Disorders"],"prefix":"10.3390","volume":"11","author":[{"given":"David","family":"Mantle","sequence":"first","affiliation":[{"name":"Pharma Nord (UK) Ltd., Telford Court, Morpeth, Northumberland NE61 2DB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain P.","family":"Hargreaves","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Liverpool John Moores University, Liverpool L3 3AF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/07315724.2001.10719063","article-title":"Biochemical Functions of Coenzyme Q10","volume":"20","author":"Crane","year":"2001","journal-title":"J. Am. Coll. Nutr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/biof.5520320121","article-title":"Functions of coenzyme Q10 in inflammation and gene expression","volume":"32","author":"Schmelzer","year":"2008","journal-title":"BioFactors"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1007\/s00415-020-09881-6","article-title":"An update on MSA: Premotor and non-motor features open a window of opportunities for early diagnosis and intervention","volume":"267","author":"Chelban","year":"2020","journal-title":"J. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(99)04137-9","article-title":"Prevalence of progressive supranuclear palsy and multiple system atrophy: A cross-sectional study","volume":"354","author":"Schrag","year":"1999","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.parkreldis.2017.12.011","article-title":"Do selective serotonin reuptake inhibitors improve survival in multiple system atrophy?","volume":"48","author":"Coon","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/mds.21839","article-title":"Survival in multiple system atrophy","volume":"23","author":"Schrag","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_7","first-page":"72","article-title":"Synucleinopathies","volume":"26","author":"Coon","year":"2020","journal-title":"Continuum"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00702-013-1133-7","article-title":"Cerebellar and parkinsonian phenotypes in multiple system atrophy: Similarities, differences and survival","volume":"121","author":"Roncevic","year":"2013","journal-title":"J. Neural Transm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3233\/JAD-170397","article-title":"Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy1","volume":"62","author":"Jellinger","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.1038\/s41598-019-42902-7","article-title":"Cerebral mitochondrial electron transport chain dysfunction in multiple system atrophy and Parkinson\u2019s disease","volume":"9","author":"Foti","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1017\/cjn.2016.261","article-title":"Oxidative Stress and Environmental Exposures are Associated with Multiple System Atrophy in Chinese Patients","volume":"43","author":"Zhou","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bpa.12678","article-title":"Oligodendroglial \u03b1-synucleinopathy-driven neuroinflammation in multiple system atrophy","volume":"29","author":"Hoffmann","year":"2019","journal-title":"Brain Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"117623","DOI":"10.1016\/j.jns.2021.117623","article-title":"COQ2 V393A confers high risk susceptibility for multiple system atrophy in East Asian population","volume":"429","author":"Porto","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3389\/fnins.2019.01187","article-title":"Reductions in COQ2 Expression Relate to Reduced ATP Levels in Multiple System Atrophy Brain","volume":"13","author":"Hsiao","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamaneurol.2016.1325","article-title":"Plasma Coenzyme Q10 Levels in Patients with Multiple System Atrophy","volume":"73","author":"Mitsui","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kasai, T., Tokuda, T., Ohmichi, T., Ishii, R., Tatebe, H., Nakagawa, M., and Mizuno, T. (2016). Serum Levels of Coenzyme Q10 in Patients with Multiple System Atrophy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147574"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.parkreldis.2018.07.017","article-title":"Clinical correlates of decreased plasma coenzyme Q10 levels in patients with multiple system atrophy","volume":"57","author":"Du","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2017.10.010","article-title":"Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy","volume":"46","author":"Compta","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/jnen\/nlw037","article-title":"Decreased Coenzyme Q10 Levels in Multiple System Atrophy Cerebellum","volume":"75","author":"Barca","year":"2016","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Schottlaender, L.V., Bettencourt, C., Kiely, A.P., Chalasani, A., Neergheen, V., Holton, J.L., Hargreaves, I., and Houlden, H. (2016). Coenzyme Q10 Levels Are Decreased in the Cerebellum of Multiple-System Atrophy Patients. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149557"},{"key":"ref_21","first-page":"1","article-title":"Multiple System Atrophy: Role of Coenzyme Q10","volume":"4","author":"Hargreaves","year":"2022","journal-title":"J. Clin. Med. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40478-019-0730-6","article-title":"Understanding the pathogenesis of multiple system atrophy: State of the art and future perspectives","volume":"7","author":"Compagnoni","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Heaton, R.A., Heales, S., Rahman, K., Sexton, D.W., and Hargreaves, I. (2020). The Effect of Cellular Coenzyme Q10 Deficiency on Lysosomal Acidification. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061923"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"14215","DOI":"10.1038\/s41598-018-32573-1","article-title":"The pathogenesis linked to coenzyme Q10 insufficiency in iPSC-derived neurons from patients with multiple-system atrophy","volume":"8","author":"Nakamoto","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12311-017-0846-9","article-title":"Three-Year Follow-Up of High-Dose Ubiquinol Supplementation in a Case of Familial Multiple System Atrophy with Compound Heterozygous COQ2 Mutations","volume":"16","author":"Mitsui","year":"2017","journal-title":"Cerebellum"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mantle, D., Heaton, R.A., and Hargreaves, I.P. (2021). Coenzyme Q10, Ageing and the Nervous System: An Overview. Antioxidants, 11.","DOI":"10.3390\/antiox11010002"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/bs.irn.2019.10.013","article-title":"Progressive supranuclear palsy","volume":"149","author":"Giagkou","year":"2019","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/s-0034-1381736","article-title":"Progressive Supranuclear Palsy","volume":"34","author":"Golbe","year":"2014","journal-title":"Semin. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s11910-004-0055-z","article-title":"Update on progressive supranuclear palsy","volume":"4","author":"Litvan","year":"2004","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s12031-011-9606-3","article-title":"Mitochondrial Dysfunction as a Therapeutic Target in Progressive Supranuclear Palsy","volume":"45","author":"Ries","year":"2011","journal-title":"J. Mol. Neurosci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1468-1331.2006.01139.x","article-title":"Aging and oxidative stress in progressive supranuclear palsy","volume":"13","author":"Aoyama","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/mds.22023","article-title":"Short-term effects of coenzyme Q10 in progressive supranuclear palsy: A randomized, placebo-controlled trial","volume":"23","author":"Stamelou","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1212\/NXI.0000000000000266","article-title":"CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial","volume":"3","author":"Apetauerova","year":"2016","journal-title":"Neurol.-Neuroimmunol. Neuroinflamm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/B978-0-444-64189-2.00014-7","article-title":"Sporadic adult-onset ataxia","volume":"155","author":"Klockgether","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/brain\/awf107","article-title":"The aetiology of sporadic adult-onset ataxia","volume":"125","author":"Abele","year":"2002","journal-title":"Brain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/B978-0-444-51892-7.00015-2","article-title":"Sporadic adult-onset ataxia of unknown etiology","volume":"103","author":"Klockgether","year":"2011","journal-title":"Handb. Clin. Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.medcli.2022.02.020","article-title":"Iodiopathic pulmonary fibrosis","volume":"159","author":"Valenzuela","year":"2022","journal-title":"Med. Clin."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Sauleda, J., N\u00fa\u00f1ez, B., Sala, E., and Soriano, J.B. (2018). Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes. Med. Sci., 6.","DOI":"10.3390\/medsci6040110"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S383","DOI":"10.1513\/AnnalsATS.201705-370AW","article-title":"Mitochondrial Dysfunction in Pulmonary Fibrosis","volume":"14","author":"Rangarajan","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/cphy.c190017","article-title":"Oxidative Stress in Pulmonary Fibrosis","volume":"10","author":"Otoupalova","year":"2020","journal-title":"Compr. Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1007\/BF00226860","article-title":"Effects of coenzymeQ10 administration on pulmonary function and exercise performance in patients with chronic lung diseases","volume":"71","author":"Fujimoto","year":"1993","journal-title":"Clin Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41420-019-0226-y","article-title":"Idebenone has preventative and therapeutic effects on pulmonary fibrosis via preferential suppression of fibroblast activity","volume":"5","author":"Sugizaki","year":"2019","journal-title":"Cell Death Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12931-022-01964-4","article-title":"CoQ10 enhances the efficacy of airway basal stem cell transplantation on bleomycin-induced idiopathic pulmonary fibrosis in mice","volume":"23","author":"Liu","year":"2022","journal-title":"Respir. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/practneurol-2021-003074","article-title":"Huntington\u2019s disease: Diagnosis and management","volume":"22","author":"Stoker","year":"2021","journal-title":"Pract. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3233\/JHD-170247","article-title":"What do we know about Late Onset Huntington\u2019s Disease?","volume":"6","author":"Chaganti","year":"2017","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/mds.21988","article-title":"The relationship between CAG repeat length and clinical progression in Huntington\u2019s disease","volume":"23","author":"Ravina","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-3-319-71779-1_3","article-title":"Mitochondrial Dysfunction in Huntington\u2019s Disease","volume":"1049","author":"Carmo","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JHD-160205","article-title":"Oxidative Stress and Huntington\u2019s Disease: The Good, The Bad, and The Ugly","volume":"5","author":"Kumar","year":"2016","journal-title":"J. Huntingt. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"577380","DOI":"10.1016\/j.jneuroim.2020.577380","article-title":"Inflammation in Huntington\u2019s disease: A few new twists on an old tale","volume":"348","author":"Santos","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ana.410410206","article-title":"Energy metabolism defects in Huntington\u2019s disease and effects of coenzyme Q10","volume":"41","author":"Koroshetz","year":"1997","journal-title":"Ann. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-7091-0579-5_13","article-title":"Coenzyme Q10 serum levels in Huntington\u2019s disease","volume":"68","author":"Andrich","year":"2004","journal-title":"J. Neural. Transm. Suppl."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington\u2019s Disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.mcn.2011.10.007","article-title":"Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington\u2019s disease","volume":"49","author":"Hickey","year":"2012","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"The Huntington Study Group (2001). A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease. Neurology, 57, 397\u2013404.","DOI":"10.1212\/WNL.57.3.397"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","article-title":"A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease","volume":"88","author":"McGarry","year":"2017","journal-title":"Neurology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mds.870110510","article-title":"A controlled trial of idebenone in Huntington\u2019s disease","volume":"11","author":"Ranen","year":"1996","journal-title":"Mov. Disord."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.conb.2021.10.002","article-title":"Alexander disease: Models, mechanisms, and medicine","volume":"72","author":"Hagemann","year":"2021","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1093\/brain\/awn178","article-title":"Adult-onset Alexander disease: A series of eleven unrelated cases with review of the literature","volume":"131","author":"Pareyson","year":"2008","journal-title":"Brain"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/jhg.2013.83","article-title":"Effects of a polymorphism in the GFAP promoter on the age of onset and ambulatory disability in late-onset Alexander disease","volume":"58","author":"Yoshida","year":"2013","journal-title":"J. Hum. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0006-8993(97)01224-9","article-title":"Advanced lipid peroxidation end-products in Alexander\u2019s disease","volume":"787","author":"Castellani","year":"1998","journal-title":"Brain Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"102415","DOI":"10.1016\/j.redox.2022.102415","article-title":"Alexander disease GFAP R239C mutant shows increased susceptibility to lipoxidation and elicits mitochondrial dysfunction and oxidative stress","volume":"55","author":"Pajares","year":"2022","journal-title":"Redox Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"ITC81","DOI":"10.7326\/AITC202006020","article-title":"Systemic Lupus Erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2165\/11598550-000000000-00000","article-title":"Late-Onset Systemic Lupus Erythematosus: Epidemiology, Diagnosis and Treatment","volume":"29","author":"Arnaud","year":"2012","journal-title":"Drugs Aging"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.2174\/0929867326666181126165139","article-title":"The Role of Mitochondria in Systemic Lupus Erythematosus: A Glimpse of Various Pathogenetic Mechanisms","volume":"27","author":"Yang","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1423-0127-21-23","article-title":"Oxidative stress and its biomarkers in systemic lupus erythematosus","volume":"21","author":"Shah","year":"2014","journal-title":"J. Biomed. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"102374","DOI":"10.1016\/j.jaut.2019.102374","article-title":"Inflammatory markers in systemic lupus erythematosus","volume":"110","author":"Aringer","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/art.41128","article-title":"Improved Mitochondrial Metabolism and Reduced Inflammation Following Attenuation of Murine Lupus with Coenzyme Q10 Analog Idebenone","volume":"72","author":"Blanco","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e000387","DOI":"10.1136\/lupus-2020-000387","article-title":"Targeting mitochondrial oxidative stress with MitoQ reduces NET formation and kidney disease in lupus-prone MRL-lpr mice","volume":"7","author":"Fortner","year":"2020","journal-title":"Lupus Sci. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"101463","DOI":"10.1016\/j.berh.2019.101463","article-title":"Antiphospholipid syndrome","volume":"34","author":"Sammaritano","year":"2019","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/1756-185X.12494","article-title":"Late-onset primary antiphospholipid syndrome in the elderly: A report of seven cases","volume":"18","author":"Cherif","year":"2014","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1182\/blood-2011-12-400986","article-title":"Mitochondrial dysfunction in antiphospholipid syndrome: Implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment","volume":"119","author":"Aguirre","year":"2012","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Nocella, C., Bartimoccia, S., Cammisotto, V., D\u2019Amico, A., Pastori, D., Frati, G., Sciarretta, S., Rosa, P., Felici, C., and Riggio, O. (2021). Oxidative Stress in the Pathogenesis of Antiphospholipid Syndrome: Implications for the Atherothrombotic Process. Antioxidants, 10.","DOI":"10.3390\/antiox10111790"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"102813","DOI":"10.1016\/j.jaut.2022.102813","article-title":"Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis","volume":"128","author":"Tektonidou","year":"2022","journal-title":"J. Autoimmun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1161\/ATVBAHA.117.309225","article-title":"Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile: A Randomized, Placebo-Controlled Trial","volume":"37","author":"Aguirre","year":"2017","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"476","DOI":"10.21037\/atm.2018.11.39","article-title":"Lysosomal storage disease overview","volume":"6","author":"Sun","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.dld.2019.12.005","article-title":"AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement","volume":"52","author":"Nascimbeni","year":"2020","journal-title":"Dig. Liver Dis."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Stepien, K.M., Roncaroli, F., Turton, N., Hendriksz, C.J., Roberts, M., Heaton, R.A., and Hargreaves, I. (2020). Mechanisms of Mitochondrial Dysfunction in Lysosomal Storage Disorders: A Review. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082596"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cca.2017.01.007","article-title":"Oxidative damage and redox in Lysosomal Storage Disorders: Biochemical markers","volume":"466","author":"Donida","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.imlet.2017.07.004","article-title":"Overview of immune abnormalities in lysosomal storage disorders","volume":"188","author":"Rigante","year":"2017","journal-title":"Immunol. Lett."},{"key":"ref_81","first-page":"1","article-title":"Coenzyme Q10 and Pyridoxal Phosphate Deficiency Is a Common Feature in Mucopolysaccharidosis Type III","volume":"25","author":"Yubero","year":"2016","journal-title":"JIMD Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41598-018-37542-2","article-title":"Plasma coenzyme Q10 status is impaired in selected genetic conditions","volume":"9","author":"Montero","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ymgme.2010.06.018","article-title":"Oxidative stress in Niemann\u2013Pick disease, type C","volume":"101","author":"Fu","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13023-017-0574-8","article-title":"Coenzyme Q10 partially restores pathological alterations in a macrophage model of Gaucher disease","volume":"12","author":"Tiscornia","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10545-013-9668-1","article-title":"Treatment effect of coenzyme Q10 and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease","volume":"37","author":"Matalonga","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"ITC33","DOI":"10.7326\/AITC202003030","article-title":"Fibromyalgia","volume":"172","author":"Bair","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_87","first-page":"169","article-title":"Oxidative stress and mitochondrial dysfunction in fibromyalgia","volume":"31","author":"Cordero","year":"2010","journal-title":"Neuro Endocrinol. Lett."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00296-019-04251-6","article-title":"Role of inflammation in the pathogenesis and treatment of fibromyalgia","volume":"39","author":"Benlidayi","year":"2019","journal-title":"Rheumatol. Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40266-021-00879-x","article-title":"Fibromyalgia in Older Individuals","volume":"38","author":"Minerbi","year":"2021","journal-title":"Drugs Aging"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1532-5415.1988.tb04364.x","article-title":"Fibromyalgia syndrome among the elderly. Comparison with younger patients","volume":"36","author":"Yunus","year":"1988","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40520-014-0238-7","article-title":"Characterization of fibromyalgia symptoms in patients 55\u201395 years old: A longitudinal study showing symptom persistence with suboptimal treatment","volume":"27","author":"Jacobson","year":"2014","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1089\/ars.2013.5260","article-title":"Can Coenzyme Q10 Improve Clinical and Molecular Parameters in Fibromyalgia?","volume":"19","author":"Cordero","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/JCP.0000000000000097","article-title":"Coenzyme Q10 Regulates Serotonin Levels and Depressive Symptoms in Fibromyalgia Patients: Results of a Small Clinical Trial","volume":"34","author":"Cordero","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/cns.12668","article-title":"Effect of Coenzyme Q10 on Psychopathological Symptoms in Fibromyalgia Patients","volume":"23","author":"Culic","year":"2017","journal-title":"CNS Neurosci. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Cordero, M.D., Cano-Garc\u00eda, F.J., Alcocer-G\u00f3mez, E., De Miguel, M., and S\u00e1nchez-Alc\u00e1zar, J.A. (2012). Oxidative Stress Correlates with Headache Symptoms in Fibromyalgia: Coenzyme Q10 Effect on Clinical Improvement. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035677"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-3-319-71779-1_13","article-title":"Clinical Features of Machado-Joseph Disease","volume":"1049","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-3-319-71779-1_11","article-title":"The Neuropathology of Spinocerebellar Ataxia Type 3\/Machado-Joseph Disease","volume":"1049","author":"Koeppen","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/jnr.22011","article-title":"Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease","volume":"87","author":"Yu","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e5805","DOI":"10.1590\/1414-431x20165805","article-title":"Lithium carbonate and coenzyme Q10 reduce cell death in a cell model of Machado-Joseph disease","volume":"49","author":"Pereira","year":"2016","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Wu, Y.-L., Chang, J.-C., Sun, H.-L., Cheng, W.-L., Yen, Y.-P., Lin, Y.-S., Chao, Y.-C., Liu, K.-H., Huang, C.-S., and Liu, K.-L. (2022). Coenzyme Q10 Supplementation Increases Removal of the ATXN3 Polyglutamine Repeat, Reducing Cerebellar Degeneration and Improving Motor Dysfunction in Murine Spinocerebellar Ataxia Type 3. Nutrients, 14.","DOI":"10.3390\/nu14173593"},{"key":"ref_101","unstructured":"Adam, M.P., Everman, D.B., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., and Amemiya, A. (2020). Multiple Acyl-CoA Dehydrogenase Deficiency. GeneReviews\u00ae, University of Washington."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.nmd.2021.01.006","article-title":"A systematic review of late-onset and very-late-onset multiple acyl-coenzyme A dehydrogenase deficiency: Cohort analysis and patient report from Taiwan","volume":"31","author":"Kuo","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1631\/jzus.B2000339","article-title":"Novel ACADVL variants resulting in mitochondrial defects in long-chain acyl-CoA dehydrogenase deficiency","volume":"21","author":"Chen","year":"2020","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.talanta.2015.02.041","article-title":"Oxidized phosphatidylcholines suggest oxidative stress in patients with medium-chain acyl-CoA dehydrogenase deficiency","volume":"139","author":"Najdekr","year":"2015","journal-title":"Talanta"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e1304","DOI":"10.1002\/cti2.1304","article-title":"Pervasive inflammatory activation in patients with deficiency in very-long-chain acyl-coA dehydrogenase (VLCADD)","volume":"10","author":"Vallejo","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1093\/hmg\/ddt232","article-title":"Secondary coenzyme Q10 deficiency and oxidative stress in cultured fibroblasts from patients with riboflavin responsive multiple Acyl-CoA dehydrogenation deficiency","volume":"22","author":"Cornelius","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neurol.2015.11.008","article-title":"Multiple acyl-CoA dehydrogenase deficiency (MADD) as a cause of late-onset treatable metabolic disease","volume":"172","author":"Souvannanorath","year":"2016","journal-title":"Rev. Neurol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/brain\/awm054","article-title":"The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene","volume":"130","author":"Gempel","year":"2007","journal-title":"Brain"},{"key":"ref_109","first-page":"9","article-title":"Clinical Overview of Leber Hereditary Optic Neuropathy","volume":"29","author":"Povilaityte","year":"2022","journal-title":"Acta Med. Litu."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/ceo.12091","article-title":"Late-onset Leber hereditary optic neuropathy","volume":"41","author":"Pfeiffer","year":"2013","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1093\/brain\/awr170","article-title":"A randomized placebo-controlled trial of idebenone in Leber\u2019s hereditary optic neuropathy","volume":"134","author":"Klopstock","year":"2011","journal-title":"Brain"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1093\/brain\/aws279","article-title":"Persistence of the treatment effect of idebenone in Leber\u2019s hereditary optic neuropathy","volume":"136","author":"Klopstock","year":"2013","journal-title":"Brain"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/WNO.0b013e318272c643","article-title":"Effects of Idebenone on Color Vision in Patients with Leber Hereditary Optic Neuropathy","volume":"33","author":"Rudolph","year":"2013","journal-title":"J. Neuro-Ophthalmol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/00041327-200020030-00006","article-title":"Do Idebenone and Vitamin Therapy Shorten the Time to Achieve Visual Recovery in Leber Hereditary Optic Neuropathy?","volume":"20","author":"Mashima","year":"2000","journal-title":"J. Neuro-Ophthalmol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/WNO.0000000000001023","article-title":"Real-World Clinical Experience with Idebenone in the Treatment of Leber Hereditary Optic Neuropathy","volume":"40","author":"Catarino","year":"2020","journal-title":"J. Neuro-Ophthalmol."}],"container-title":["Antioxidants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3921\/11\/11\/2293\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:22:05Z","timestamp":1760145725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3921\/11\/11\/2293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"references-count":115,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["antiox11112293"],"URL":"https:\/\/doi.org\/10.3390\/antiox11112293","relation":{},"ISSN":["2076-3921"],"issn-type":[{"value":"2076-3921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,19]]}}}